Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report.
Diagn Microbiol Infect Dis
; 99(4): 115272, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-938872
ABSTRACT
Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Invasive Pulmonary Aspergillosis
/
Antibodies, Monoclonal, Humanized
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Diagnostic study
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Diagn Microbiol Infect Dis
Year:
2021
Document Type:
Article
Affiliation country:
J.diagmicrobio.2020.115272
Similar
MEDLINE
...
LILACS
LIS